This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
by Zacks Equity Research
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
Disc Medicine (IRON) Down on Mixed Results From AURORA Study
by Zacks Equity Research
Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.
How Much Upside is Left in Disc Medicine, Inc. (IRON)? Wall Street Analysts Think 38.17%
by Zacks Equity Research
The mean of analysts' price targets for Disc Medicine, Inc. (IRON) points to a 38.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why
by Zacks Equity Research
Disc Medicine, Inc. (IRON) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is a Surprise Coming for Disc Medicine (IRON) This Earnings Season?
by Zacks Equity Research
Disc Medicine (IRON) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Disc Medicine, Inc. (IRON) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Disc Medicine, Inc. (IRON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Disc Medicine, Inc. (IRON) Is Up 4.40% in One Week: What You Should Know
by Zacks Equity Research
Does Disc Medicine, Inc. (IRON) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com featured highlights Harrow Health and Disc Medicine Opco
by Zacks Equity Research
Harrow Health and Disc Medicine Opco have been highlighted in this Screen of The Week article.
2 Stocks in Focus as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Harrow Health (HROW) and Disc Medicine (IRON).
Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Disc Medicine, Inc. (IRON) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
3 Stocks in the Limelight on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Disc Medicine (IRON), Westamerica (WABC) and Enliven (ELVN).